Nutra Pharma (OTCMKTS:NPHC – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Nutra Pharma and Editas Medicine, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutra Pharma | 0 | 0 | 0 | 0 | 0.00 |
| Editas Medicine | 1 | 1 | 5 | 0 | 2.57 |
Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 119.07%. Given Editas Medicine’s stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Nutra Pharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Nutra Pharma | -429.26% | N/A | -106.42% |
| Editas Medicine | -281.59% | -677.39% | -58.25% |
Valuation & Earnings
This table compares Nutra Pharma and Editas Medicine”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutra Pharma | $390,000.00 | 5.51 | -$1.29 million | N/A | N/A |
| Editas Medicine | $40.52 million | 5.96 | -$160.06 million | ($1.23) | -2.00 |
Nutra Pharma has higher earnings, but lower revenue than Editas Medicine.
Volatility and Risk
Nutra Pharma has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500.
Insider & Institutional Ownership
71.9% of Editas Medicine shares are held by institutional investors. 61.5% of Nutra Pharma shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Editas Medicine beats Nutra Pharma on 9 of the 12 factors compared between the two stocks.
About Nutra Pharma
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Nutra Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutra Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
